Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants

NCT01861730 is registered in ClinicalTrials.gov with Aeras as lead sponsor.

NCT NCT01861730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01861730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants
Lead sponsor
Aeras
Phase
Phase 1/2
Overall status
Completed
Start date
July 1, 2013
Completion date
December 22, 2017
Enrollment
243 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis